IDEAYA Biosciences Inc (NASDAQ:IDYA), a United States-based oncology-focused biotechnology company, has dosed its first patient in the phase one combination study of IDE196 and binimetinib, an MEK inhibitor, intended to treat metastatic uveal melanoma (MUM), it was reported on Thursday.
The company is assessing the clinical combination of IDE196 and binimetinib, which is being provided by Pfizer based on a clinical trial collaboration and supply contract.
The company expects interim data from the MEK combination study in late 2021 to early 2022, when the firm will assess a potential registrational path for MUM and a potential collaboration.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis